Multiple Myeloma Research Foundation

Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.

Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.